 |
Market Cap | 8.77M | EPS (ttm) | -59.67 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 9.56% |
P/S | 0.79 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -13.46% |
Dividend | - | Sales Q/Q | 39.06% |
Insider Own | 18.89% | Inst Own | 10.37% |
Insider Trans | -84.47% | Inst Trans | 50.26% |
Short Float | 2.42% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 11.31M | 52W Range | 0.24 - 35.80 |
|
|
|
iCoreConnect, Inc. engages in the provision of cloud-based software and technology. It is focused on increasing workflow productivity and customer profitability through its enterprise platform of application and services. The company was founded in 1992 and is headquartered in Ocoee, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Fundamental Global Inc. | 10% Owner | Dec 10 '24 | Sale | 0.27 | 1,000,000 | 269,000 | 1,223,843 | Dec 12 09:46 PM | Fundamental Global Inc. | 10% Owner | Dec 12 '24 | Sale | 0.17 | 10,000 | 1,725 | 1,213,843 | Dec 12 09:46 PM | Pasqual John | Director | Aug 27 '24 | Buy | 0.58 | 5,000 | 2,900 | 122,016 | Dec 09 05:00 PM | McDermott Robert P | Chief Executive Officer | Nov 25 '24 | Buy | 0.18 | 236,785 | 42,621 | 1,229,885 | Dec 06 05:00 PM | McDermott Robert P | Chief Executive Officer | Nov 26 '24 | Buy | 0.17 | 40,000 | 6,800 | 1,269,885 | Dec 06 05:00 PM |
|
|
 |
 |
Market Cap | 3.15M | EPS (ttm) | -1.13 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -10.56% |
P/S | - | EPS next 5Y | - |
P/B | 2.99 | EPS Q/Q | 37.58% |
Dividend | - | Sales Q/Q | - |
Insider Own | 13.43% | Inst Own | 5.18% |
Insider Trans | 0.00% | Inst Trans | -3.53% |
Short Float | 2.85% | Earnings | - |
Analyst Recom | 1.00 | Target Price | 16.00 |
Avg Volume | 2.39M | 52W Range | 0.18 - 1.87 |
|
|
|
Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY. |
|
 |
 |
Market Cap | 47.62M | EPS (ttm) | -0.11 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 0.67 | EPS Q/Q | -765.12% |
Dividend | - | Sales Q/Q | - |
Insider Own | - | Inst Own | 0.35% |
Insider Trans | - | Inst Trans | - |
Short Float | - | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 3.37M | 52W Range | 1.30 - 13.40 |
|
|
|
OSR Holdings, Inc. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA. |
|
|  |
 |
Market Cap | 6.75M | EPS (ttm) | -2.92 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 51.16% |
P/S | 675.20 | EPS next 5Y | - |
P/B | 3.28 | EPS Q/Q | 90.54% |
Dividend | - | Sales Q/Q | 300.00% |
Insider Own | 13.75% | Inst Own | 4.51% |
Insider Trans | -1.34% | Inst Trans | -44.60% |
Short Float | 3.75% | Earnings | - |
Analyst Recom | 3.00 | Target Price | 1125.00 |
Avg Volume | 326.24K | 52W Range | 1.31 - 18.50 |
|
|
|
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Vieser Jaime | Director | Dec 31 '24 | Sale | 2.01 | 3,000 | 6,022 | 25,894 | Jan 03 04:34 PM | Vieser Jaime | Director | Dec 31 '24 | Proposed Sale | 2.17 | 3,000 | 6,510 | | Dec 31 05:10 PM |
|
|
 |
 |
Market Cap | 3.03M | EPS (ttm) | -29.10 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 51.86% |
P/S | 3.88 | EPS next 5Y | - |
P/B | 1.07 | EPS Q/Q | 89.80% |
Dividend | - | Sales Q/Q | -49.58% |
Insider Own | 0.14% | Inst Own | 2.54% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 3.49% | Earnings | Mar 21/a |
Analyst Recom | - | Target Price | - |
Avg Volume | 644.45K | 52W Range | 2.43 - 31.45 |
|
|
|
Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company was founded by Jennifer Ernst and John Claude on September 22, 2016 and is headquartered in Fremont, CA. |
|
|  |
 |
Market Cap | 2.90M | EPS (ttm) | -452.26 |
P/E | - | EPS this Y | 81.87% |
Forward P/E | - | EPS next Y | 8.52% |
PEG | - | EPS past 5Y | 80.96% |
P/S | - | EPS next 5Y | 51.40% |
P/B | 0.61 | EPS Q/Q | 99.12% |
Dividend | - | Sales Q/Q | - |
Insider Own | 0.01% | Inst Own | 3.33% |
Insider Trans | 0.00% | Inst Trans | 26.57% |
Short Float | 8.26% | Earnings | Feb 14/b |
Analyst Recom | 1.00 | Target Price | 21.00 |
Avg Volume | 514.96K | 52W Range | 0.94 - 180.19 |
|
|
|
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA. |
|
 |
 |
Market Cap | 179.62M | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | - |
Dividend | - | Sales Q/Q | - |
Insider Own | 72.17% | Inst Own | - |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | - | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 54.67K | 52W Range | 6.91 - 25.00 |
|
|
|
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Los Angeles, CA. |
|
|  |
 |
Market Cap | 29.99M | EPS (ttm) | -14.11 |
P/E | - | EPS this Y | 60.22% |
Forward P/E | - | EPS next Y | 40.44% |
PEG | - | EPS past 5Y | - |
P/S | 0.79 | EPS next 5Y | 32.86% |
P/B | - | EPS Q/Q | 48.01% |
Dividend | - | Sales Q/Q | 46.66% |
Insider Own | 60.66% | Inst Own | 7.26% |
Insider Trans | 38.12% | Inst Trans | -21.53% |
Short Float | 1.44% | Earnings | Mar 31/a |
Analyst Recom | 1.00 | Target Price | 7.50 |
Avg Volume | 10.13K | 52W Range | 1.18 - 3.33 |
|
|
|
Local Bounti Corp. operates as an advanced indoor growing facility. It is a premier Controlled Environment Agriculture (CEA) company redefining conversion efficiency and environmental, social and governance standards for indoor agriculture. The company was founded by Travis Joyner and Craig M. Hurlbert in August 2018 and is headquartered in Hamilton, MT. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Schwab Charles R. | 10% Owner | Mar 31 '25 | Buy | 2.00 | 1,700,723 | 3,401,446 | 1,700,723 | Apr 02 05:14 PM | SCHWAB CHARLES R JR. | Director | Mar 31 '25 | Buy | 2.00 | 70,863 | 141,726 | 70,863 | Apr 02 05:09 PM | Carr-Smith Jennifer | Director | Dec 17 '24 | Sale | 1.48 | 21,237 | 31,431 | 14,880 | Jan 24 04:25 PM | Joyner Travis M. | Chief Technology Officer | Dec 20 '24 | Buy | 1.86 | 500 | 928 | 59,637 | Dec 23 05:14 PM | Joyner Travis M. | Chief Technology Officer | Dec 19 '24 | Buy | 1.79 | 2,850 | 5,115 | 59,137 | Dec 20 09:09 AM |
|
|
 |
 |
Market Cap | 115.35M | EPS (ttm) | 0.03 |
P/E | 210.16 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 25.30 | EPS next 5Y | - |
P/B | 66.56 | EPS Q/Q | 124.66% |
Dividend | - | Sales Q/Q | -32.55% |
Insider Own | 93.29% | Inst Own | 0.56% |
Insider Trans | 0.00% | Inst Trans | 0.12% |
Short Float | 0.12% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 69.18K | 52W Range | 2.80 - 10.59 |
|
|
|
Creative Global Technology Holdings Ltd. engages in sourcing and reselling recycled consumer electronic devices through its subsidiary. The company was founded in 2016 and is headquartered in Hong Kong. |
|
 |
 |
Market Cap | 187.94M | EPS (ttm) | 1.88 |
P/E | 19.62 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 4.42% |
P/S | 2.19 | EPS next 5Y | - |
P/B | 1.62 | EPS Q/Q | 92.73% |
Dividend | 1.52% | Sales Q/Q | 1.03% |
Insider Own | 14.02% | Inst Own | 32.49% |
Insider Trans | 0.00% | Inst Trans | 1.30% |
Short Float | 0.20% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 7.31K | 52W Range | 13.49 - 30.95 |
|
|
|
Old Point Financial Corp. operates as a bank holding company, which engages in the provision of banking services through its subsidiaries. It offers various consumer, mortgage, and business banking services, including loan, deposit, and cash management services. The company was founded on February 16, 1984 and is headquartered in Hampton, VA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Golden Sarah B | Director | Jul 30 '24 | Buy | 18.00 | 900 | 16,200 | 7,588 | Aug 05 09:41 AM | Golden Sarah B | Director | Jul 31 '24 | Buy | 19.45 | 500 | 9,725 | 8,088 | Aug 05 09:41 AM | Golden Sarah B | Director | Aug 01 '24 | Buy | 19.40 | 500 | 9,700 | 8,588 | Aug 05 09:41 AM | Golden Sarah B | Director | Aug 02 '24 | Buy | 18.81 | 495 | 9,311 | 9,083 | Aug 05 09:41 AM | WITT JOSEPH R | President/Financial Svcs, CSO | Jul 31 '24 | Buy | 19.32 | 70 | 1,352 | 21,976 | Aug 01 11:29 AM |
|
|
|